Key result
Inclisiran significantly reduces LDL cholesterol levels compared to placebo in heterozygous familial hypercholesterolemia.
Why the study?
Does inclisiran reduce LDL cholesterol levels compared to placebo in adults with heterozygous familial hypercholesterolemia?
Does inclisiran reduce LDL cholesterol levels compared to placebo in adults with heterozygous familial hypercholesterolemia?
Answers are grounded in this paper and cite their sources.
Inclisiran significantly reduces LDL cholesterol levels with an infrequent dosing regimen and an acceptable safety profile in adults with heterozygous familial hypercholesterolemia.
Among adults with heterozygous familial hypercholesterolemia, those who received inclisiran had significantly lower levels of LDL cholesterol than those who received placebo, with an infrequent dosing regimen and an acceptable safety profile. (Funded by the Medicines Company; ORION-9 ClinicalTrials.gov number, NCT03397121.).
No takes yet. Share an insight, caveat, or question.
Raal et al. (2020) studied this question. Inclisiran significantly reduced LDL cholesterol levels compared to placebo in adults with heterozygous familial hypercholesterolemia, with an infrequent dosing regimen and acceptable safety profile.
Synapse has enriched 10 related papers. Consider them for comparative context: